Drug interactions
Dabigatran + Ulipristal
Severity: Moderate
Dabigatran and Ulipristal: moderate interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Ulipristal may inhibit intestinal P-glycoprotein and raise dabigatran exposure, increasing bleeding risk. The effect is greatest in patients with reduced renal function.
What this interaction means in plain words
Dabigatran and Ulipristal can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken.
Why it happens
P-glycoprotein inhibition by ulipristal reduces efflux of dabigatran etexilate, increasing absorption.
What to do
Monitor for bleeding after ulipristal use, particularly in renal impairment. Avoid the combination if CrCl falls below the dabigatran label thresholds for P-gp inhibitors.
What to ask your pharmacist
- Should I take them at different times of day?
- Does the dose of either medicine need to change?
- Is there anything I should avoid, such as alcohol or certain foods, while on both?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Dabigatran and Ulipristal, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 14 days on the web. No card needed.
Frequently asked questions
Can I take Dabigatran with Ulipristal?
MediHelp rates the interaction as moderate. Dabigatran and Ulipristal can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken. Ulipristal may inhibit intestinal P-glycoprotein and raise dabigatran exposure, increasing bleeding risk. The effect is greatest in patients with reduced renal function.
How serious is the interaction between Dabigatran and Ulipristal?
MediHelp rates it moderate, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Monitor for bleeding after ulipristal use, particularly in renal impairment. Avoid the combination if CrCl falls below the dabigatran label thresholds for P-gp inhibitors.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
